Floatz logo

Ramelteon

Insomnia

TakedaSmall moleculePhase 4 / ApprovedDormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Insomnia cohort.

Asset / SponsorPhaseRating
Eszopiclone
University of California, Los Angeles
Phase 4A
Cipralex
University of California, Los Angeles
Phase 4BBB
LEMBOREXANT
YangPan
Phase 4BBB
Suvorexant
Mayo Clinic
Phase 4BBB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
University of California, San Diego
Phase 3BB

View all 40 →

Same molecule, other indications

Ramelteon is also rated in:

bipolar disorderDormant
CCC
Indicative ·
51 / 100
View asset →
migraine disorderDormant
CCC
Indicative ·
49 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →